KGM-PTX + CSM

KGM-PTX + CSM is a combination drug product reported in research literature as a codelivery system for cancer therapy. It likely refers to a composite hydrogel system that contains konjac glucomannan (KGM)-based hydrogel loaded with paclitaxel (PTX) and a component referred to as CSM (likely chitosan microspheres or similar polymeric component), designed for sequential and localized release of chemotherapy agents into the tumor microenvironment. Paclitaxel is a well-established antineoplastic agent that stabilizes microtubules and inhibits mitosis, resulting in cell cycle arrest and apoptosis in tumor cells. The KGM hydrogel component provides sustained local release and improved tumor penetration. The system is designed to improve the efficacy of PTX by delivering it more effectively and minimizing systemic toxicity. Published research describes similar co-delivery strategies and hydrogel-based local administration approaches for enhanced antitumor effects.